Opinion
Video
ASCO 2024: Key Findings of the LAURA Trial on Osimertinib for EGFR-Mutated NSCLC
Author(s):
Key Takeaways
- Osimertinib significantly improved progression-free survival in unresectable stage III EGFR-mutated NSCLC post-definitive CRT, as shown in the phase 3 LAURA trial.
- The trial results suggest osimertinib may become a new standard of care for patients with EGFR-mutated NSCLC, enhancing treatment strategies.
Jason Porter, MD, analyzes critical insights from the 2024 ASCO Annual Meeting presentation on progression-free survival data from the LAURA phase 3 trial, which evaluated osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer who did not progress after definitive chemoradiotherapy.
Video content above is prompted by the following questions:
- Discuss the data that was presented at the 2024 ASCO Annual Meeting on the progression-free survival from the phase 3 trial LAURA of osimertinib in patients with unresectable stage III EGFR-mutated NSCLC without progression after definitive CRT.
- What are your key takeaways from this study and how will it impact the current standard of care for EGFR-mutated NSCLC?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Videos
Related Content
March 28th 2025
January 1st 2025
